hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy

详细信息    查看全文

• 作者：Jianming Qiu (1)
  Guangen Yang (1)
  Zhong Shen (1)
  Ya Xie (1)
  Lewei Wang (1)
  
• 关键词：Human phosphatidylethanolamine ; binding protein 4 ; Predictive marker ; Rectal cancer ; Preoperative radiotherapy
• 刊名：International Journal of Colorectal Disease
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：28
• 期：2
• 页码：241-246
• 参考文献：1. Janjan NA, Khoo VS, Abbruzzese J et al (1999) Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M.D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys 44:1027-038 CrossRef
  2. Theodoropoulos G, Wise WE, Padmanabhan A et al (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45:895-03 CrossRef
  3. Kaminsky-Forrett MC, Conroy T, Luporsi E et al (1998) Prognostic implications of downstaging following preoperative radiation therapy for operable T3–T4 rectal cancer. Int J Radiat Oncol Biol Phys 42:935-41 CrossRef
  4. Chan AK, Wong AO, Langevin J et al (2000) Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys 48:843-56 CrossRef
  5. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697-705 CrossRef
  6. Stelzmueller I, Zitt M, Aigner F et al (2009) Postoperative morbidity following chemoradiation for locally advanced low rectal cancer. J Gastrointest Surg 13:657-67 CrossRef
  7. Lin LC, Lee HH, Hwang WS et al (2006) p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 15:211-16 CrossRef
  8. Kuremsky JG, Tepper JE, McLeod HL (2009) Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673-88 CrossRef
  9. Lenart P, Petronczki M, Steegmaier M, Di FB, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of Polo-like kinase 1. Curr Biol 17:304-15 CrossRef
  10. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ (2007) BI 2536, a potent and selective inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-22 CrossRef
  11. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP (2005) ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent. Cancer Cell 7:275-86 CrossRef
  12. McInnes C, Mezna M, Fischer PM (2005) Progress in the discovery of Polo-like kinase inhibitors. Curr Top Med Chem 5:181-97 CrossRef
  13. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG (2009) Distinct concentration dependent effects of the Polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69:6969-977 CrossRef
  14. Wang X, Li N, Liu B et al (2004) A novel human phosphatidylethanolamine-binding protein resists TNF-α-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem 279:45855-5864 CrossRef
  15. Wang X, Li N, Li H et al (2005) Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to TNF-α-induced apoptosis and cell growth arrest. Clin Cancer Res 11:7545-553 CrossRef
  16. Li H, Wang X, Li N et al (2007) hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem 282:4943-950 CrossRef
  17. Li P, Wang X, Li N et al (2006) Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med 18:505-10
  18. Zhang Y, Wang X, Xiang Z et al (2007) Promotion of cellular migration and apoptosis resistance by a mouse eye-specific phosphatidylethanolamine-binding protein. Int J Mol Med 19:55-3
  19. Gogineni VR, Kargiotis O, Klopfenstein JD et al (2009) RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells. Int J Oncol 34(1):209-18
  20. Corn BW, Kovner F, Bek S et al (2008) ERK signaling in colorectal cancer: a preliminary report on the expression of phosphorylated ERK and the effects of radiation therapy. Am J Clin Oncol 31(3):255-58 CrossRef
  21. Kang YH, Lee SJ (2008) Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol Rep 20(3):637-43
  22. Wang Y, Liu L, Zhou D (2011) Inhibition of p38 MAPK attenuates ionizing radiation-induced hematopoietic cell senescence and residual bone marrow injury. Radiat Res 176(6):743-52 CrossRef
  23. Ho SY, Wu WJ, Chiu HW et al (2011) Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. Chem Biol Interact 193(2):162-71 CrossRef
  24. Nix P, Cawkwell L, Patmore H et al (2005) Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 92:2185-189 CrossRef
  25. del Franz Ro, Sarah Keppner, Gianni Capalbo et al (2010) Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 27:918-29
  26. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-3 CrossRef
  27. Perez RO (2011) Predicting response to neoadjuvant treatment for rectal cancer: a step toward individualized medicine. Dis Colon Rectum 54(9):1057-058 CrossRef
  28. Shioya M, Takahashi T, Ishikawa H et al (2011) Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer. J Cancer Res Clin Oncol J Radiat Res 52(6):821-27
  29. Shinto E, Hashiguchi Y, Ueno H et al (2011) Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum 54(9):1098-106 CrossRef
  30. Kim K, Chie EK, Wu HG et al (2011) High surviving expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 26(8):1019-023 CrossRef
  31. Improved survival with preoperative radiotherapy in resectable rectal cancer Swedish Rectal Cancer Trial (1997) N Engl J Med 336:980-87
  32. Meyn RE, Milas L, Ang KK (2009) The role of apoptosis in radiation oncology. Int J Radiat Biol 85:107-15 CrossRef
  33. Yang JY, Xia W, Hu MC (2006) Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol 29:643-48
  
• 作者单位：Jianming Qiu (1)
  Guangen Yang (1)
  Zhong Shen (1)
  Ya Xie (1)
  Lewei Wang (1)
  
  1. Department of Colorectal Surgery, The Third People’s Hospital of Hangzhou, Hangzhou, China
  
• ISSN：1432-1262

文摘

Purpose The ability to predict tumor sensitivity toward radiotherapy is important in the personalized application of preoperative radiotherapy for patients with rectal cancer. The aim of the present study was to test the human phosphatidylethanolamine-binding protein 4 (hPEBP4) as a predictive marker of tumor response to preoperative radiotherapy in patients with rectal cancer. Method A retrospective analysis was conducted, consisting of 86 patients with locally advanced rectal cancer who underwent short-course preoperative radiotherapy (20?Gy in five fractions for 1?week) followed by a radical resection. Both pretreatment biopsy specimens and resected primary tumor tissue were collected. Immunohistochemistry and tumor regression grading system were used to evaluate the expression of hPEBP4 in the pretreatment biopsy specimens and the response of rectal cancer to radiotherapy, respectively. Expression of hPEBP4 was correlated with tumor regression in the resected specimen and the clinical outcome of the patients as well. Results We found that high expression of hPEBP4 was associated with radioresistance in both univariate and multivariate analyses, and patients with a high hPEBP4 expression had a poorer progression-free survival than those with low hPEBP4 expression. Conclusion Our study revealed the independent predictive values of hPEBP4 in response of rectal cancer to preoperative radiotherapy, which suggests that upregulating hPEBP4 might be a potential mechanism by which rectal cancer cells avoid the destructive effects of radiotherapy.